Le Lézard
Classified in: Health
Subjects: PDT, FDA

La Roche-Posay Changes The Face Of Acne With Latest FDA Approved Acne Ingredient And Premieres Artificial Intelligence-Based Skin Analysis

NEW YORK, July 10, 2019 /PRNewswire/ -- La Roche-Posay is committed to improving access to dermatological care for people with acne, which affects over 50 million Americans. La Roche-Posay announces the launch of Effaclar Adapalene Gel 0.1% Acne Treatment, containing adapalene, a prescription-strength retinoid acne treatment, now available over-the-counter. La Roche-Posay is also launching My Skin Track PoreScan, their first skin analysis powered by artificial intelligence. La Roche-Posay is providing consumers new and innovative tools developed with dermatologists to address their skin concerns.

Over the past 3 decades, OTC (over-the-counter) acne treatments have been limited to only a handful of active ingredients, mostly with benzoyl peroxide and salicylic acid. These ingredients are widely used by consumers, as the vast majority of people with acne don't consult a dermatologist to get a prescription.

La Roche-Posay now offers a topical prescription-strength retinoid (adapalene) acne treatment in addition to its award-winning Effaclar Duo micronized benzoyl peroxide acne treatment. The American Academy of Dermatology (AAD) describes topical retinoids and benzoyl peroxide as first line treatments for mild to severe acne.

"There are many effective acne prescriptions including combinations of benzoyl peroxide and topical retinoids. However, many don't have access to these prescriptions because they don't visit a dermatologist or their insurance won't cover it. OTC prescription-strength acne treatments are a game-changer for people who have limited access to a health care provider. It allows earlier access to treatment which can help prevent scarring." - Hilary Baldwin, MD, Board Certified Dermatologist

Along with skincare, La Roche-Posay believes better-looking skin starts with a personalized skin analysis and skincare regimen. Recognizing that many consumers are confused about which products are right for their skin type and concern, La Roche-Posay is launching My Skin Track PoreScan. This tool uses artificial intelligence to make personalized skincare recommendations for those concerned with clogged pores, raised imperfections, and residual marks

"My Skin Track PoreScan not only provides consumers access to a personalized skincare regimen upon their initial skin analysis, but it also allows them to track changes in their skin after completing their regimen. This will provide insights into how to adapt their daily skincare routine with new product recommendations based on their new needs." ? Adrien Dissous, VP of Maketing for La Roche-Posay USA

To create this innovative tool, La Roche-Posay partnered with dermatologists from around the world to analyze more than 6,000 images of men and women of multiple ethnicities, ages, and skin types. My Skin Track PoreScan was presented at the Worldwide Congress of Dermatology in June of 2019.

Recommended by 90,000 dermatologists worldwide, La Roche-Posay's mission is to offer a better life for sensitive skin. Created by a pharmacist in 1975, the brand is now present in over 60 countries. It offers a unique range of daily skincare developed for every skin type to complement their patients' treatments and promote good skincare practices adapted to each skin concern. The brand develops formulas with its exclusive Selenium-rich water, also used at its Thermal Center, the first Dermatology Center in Europe, due to its antioxidant and soothing properties. The products are developed using a strict formulation charter with a minimal number of ingredients and are formulated at optimal concentrations. Additionally, La Roche-Posay products undergo stringent clinical testing for efficacy and safety, even on sensitive skin. The key La Roche-Posay product ranges are: Lipikar (dry skin), Anthelios (photoprotection), Effaclar (acne) and Toleriane (sensitive skin).

For additional information about La Roche-Posay, visit www.laroche-posay.us and follow La Roche-Posay USA on Facebook, Instagram and Twitter @LaRochePosayUSA

La Roche-Posay Declares Most Successful Sun Safety Year Yet (PRNewsfoto/La Roche-Posay)

SOURCE La Roche-Posay

These press releases may also interest you

9 jui 2020
Carromex, a mathematical research-based innovation company based in Australia, unveiled a new cloud-based pharmaceutical software platform called Pharma Leads https://carromex.com/products/pharma-leads/, that is set to significantly contribute to the...

9 jui 2020
Award-winning actress and producer, American Institute for Stuttering Board Member, and longtime supporter, Emily Blunt hosted the 14th annual American Institute for Stuttering's (AIS) Benefit Gala, which went virtual this year due to the Covid-19...

9 jui 2020
The zebrafish has been utilised as a model organism for biomedical research globally for half a century, mainly due to the high genetic similarity (over 70%) between zebrafish and human genes, with over 80% of human morbid genes related to at least...

9 jui 2020
Aurora Spine Corporation ("Aurora Spine" or the "Company") announces financial results for the First Quarter 2020, ended March 31, 2020.  All figures are in U.S. dollars. To our Shareholders: Q1 2020 started strongly for the Company based on...

9 jui 2020
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to utilizing proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, today announced the...

9 jui 2020
efficacyAI, Inc. announced today that it has recently signed a license agreement with the Georgia Tech Research Corporation granting it exclusive rights to the use of a suite of algorithms called MedicascyAI. This novel artificial intelligence...

News published on 10 july 2019 at 08:07 and distributed by: